Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease
- PMID: 10406992
- PMCID: PMC1736504
- DOI: 10.1136/jnnp.67.2.209
Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: relation to Alzheimer's disease
Abstract
Objectives: Dementia associated with Lewy bodies in cortical and subcortical areas is classified as dementia of the non-Alzheimer type and termed diffuse Lewy body disease (DLBD). The generic term "dementia with Lewy bodies (DLB)" was proposed in the international workshop on Lewy body dementia to include the similar disorders presenting Lewy bodies. In DLB, a lower level of choline acetyltransferase (ChAT) activity in the neocortex was found compared with that in Alzheimer's disease. The purpose of the present study was to determine the total amount of muscarinic acetylcholine receptors (mAChRs) and relative proportion of each subtype (m1-m4) of mAChRs in the frontal and temporal cortex of seven DLBD and 11 Alzheimer's disease necropsied brains.
Methods: A [(3)H]quinuclidinyl benzilate (QNB) binding assay and an immunoprecipitation assay using subtype-specific antibodies were performed. Each antibody was raised against fusion proteins containing peptides corresponding to the third intracellular (i3) loops of the respective mAChR subtype.
Results: The total amounts of mAChRs were significantly lower in the preparations of temporal cortices from DLBD and Alzheimer's disease than in those from dead controls (seven cases). In both diseases, the proportion of the m3 receptor in the frontal cortex was significantly increased and that of the m4 receptor in the temporal cortex was significantly decreased compared with the control specimens. The proportions of the m1 and m2 subtypes were significantly different in the temporal cortex. The proportion of the m1 receptor was significantly greater in the DLBD brains, whereas that of the m2 receptor was significantly greater in the Alzheimer's disease brains than in the controls.
Conclusions: The m1 receptor is the major subtype in the cerebral cortex, and m2 is known to be present at presynaptic terminals. The higher proportions of m1 in DLBD and m2 in Alzheimer's disease suggest that the manner of degeneration in the cholinergic system is different between the diseases. It is hypothesised that a severe depletion of presynaptic cholinergic projective neurons causes the upregulation of m1 receptor in the temporal cortex in DLBD.
Comment in
-
Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease.J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):253-4. doi: 10.1136/jnnp.68.2.253. J Neurol Neurosurg Psychiatry. 2000. PMID: 10702044 Free PMC article. No abstract available.
Similar articles
-
Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.J Chem Neuroanat. 2003 Mar;25(3):161-73. doi: 10.1016/s0891-0618(03)00002-4. J Chem Neuroanat. 2003. PMID: 12706204
-
Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease.J Neurol Sci. 2004 Aug 30;223(2):145-8. doi: 10.1016/j.jns.2004.05.002. J Neurol Sci. 2004. PMID: 15337615
-
Alterations of muscarinic acetylcholine receptors in atypical Pick's disease without Pick bodies.J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):965-7. doi: 10.1136/jnnp.74.7.965. J Neurol Neurosurg Psychiatry. 2003. PMID: 12810794 Free PMC article.
-
Diffuse Lewy body disease.Intern Med. 1998 Jan;37(1):6-10. doi: 10.2169/internalmedicine.37.6. Intern Med. 1998. PMID: 9510392 Review.
-
Lewy body disease and dementia. A review.Arch Intern Med. 1996 Mar 11;156(5):487-93. Arch Intern Med. 1996. PMID: 8604954 Review.
Cited by
-
Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease.Curr Neuropharmacol. 2017;15(4):480-494. doi: 10.2174/1570159X14666160325121145. Curr Neuropharmacol. 2017. PMID: 27012953 Free PMC article. Review.
-
T-495, a novel low cooperative M1 receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk.Pharmacol Res Perspect. 2020 Feb;8(1):e00560. doi: 10.1002/prp2.560. Pharmacol Res Perspect. 2020. PMID: 31990455 Free PMC article.
-
Motor cortex inhibitory circuits in dementia with Lewy bodies and in Alzheimer's disease.J Neural Transm (Vienna). 2006 Nov;113(11):1679-84. doi: 10.1007/s00702-006-0551-1. Epub 2006 Oct 6. J Neural Transm (Vienna). 2006. PMID: 17024328
-
Cholinergic imaging in dementia spectrum disorders.Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1376-86. doi: 10.1007/s00259-016-3349-x. Epub 2016 Mar 16. Eur J Nucl Med Mol Imaging. 2016. PMID: 26984612 Free PMC article. Review.
-
Hallucinations in neurodegenerative diseases.CNS Neurosci Ther. 2012 Feb;18(2):149-59. doi: 10.1111/j.1755-5949.2011.00247.x. CNS Neurosci Ther. 2012. PMID: 21592320 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical